Share
Vagus nerve stimulation (VNS) is an established treatment option for patients with drug-resistant epilepsy. However, while approximately half of patients respond positively to this therapy, the remaining patients experience little or no significant therapeutic benefit. Currently, there is no standard method capable of reliably distinguishing future responders from non-responders prior to device implantation. CEITEC Masaryk University offers a patented technology that enables highly reliable prediction of clinical response to VNS therapy based on routinely available preoperative EEG data.
Technology Description
The technology is based on a statistical model that analyzes relative EEG power parameters obtained during a standard preoperative examination. The model processes data recorded during a stimulation protocol comprising eight conditions (resting state, eye opening, photic stimulation, and hyperventilation). The method is fully non-invasive and does not require any additional examinations or increased burden on the patient. It utilizes data routinely collected in clinical practice, facilitating its integration into existing diagnostic workflows.
Key Benefits
- Personalized epilepsy treatment through more accurate selection of candidates for VNS therapy.
- Reduction of unnecessary surgical procedures in patients with a low probability of therapeutic response.
- Lower healthcare costs through more efficient use of VNS implants and associated care.
- Easy integration into clinical practice without the need for new equipment or specialized examinations.
Fields of Application
The technology is particularly relevant for:
- Manufacturers of vagus nerve stimulation systems.
- Healthcare providers specializing in epilepsy treatment.
- Healthcare payers and organizations focused on optimizing treatment financing.
- Manufacturers of EEG diagnostic devices and software solutions.
Intellectual Property Protection
The technology is protected by European Patent EP3437692B1.
Development Stage
TRL 4 – Technology validated in a laboratory environment.
Research Team
The technology was developed by the Behavioural and Social Neuroscience Research Group led by Prof. Milan Brázdil, MD, PhD, FRCP, at CEITEC Masaryk University.
Seeking Collaboration Partners
We are seeking partners interested in technology licensing, industrial collaboration, and further joint development in the field of epilepsy diagnostics and personalized treatment. For more information about commercialization opportunities and potential collaboration, please contact us.
